Clinical Trial Update: PET/CT Imaging of uPAR-expression in Patients With Neuroendocrine Tumors Using 68Ga-NOTA-AE105 [Phase 2]

View source ↗

Summary

Phase 2 clinical trial updating PET/CT imaging of uPAR-expression in patients with neuroendocrine tumors using 68Ga-NOTA-AE105; study completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neuroendocrine Tumors

Drugs mentioned

• 68Ga-NOTA-AE105 (NOTA-AE105 radiotracer)

Snippet

Sponsor: Rigshospitalet, Denmark | Conditions: Neuroendocrine Tumors | Phase 2 | Status: COMPLETED